Home > Reference



  1. Kam K. M., Luey K. Y., Fung S. M., Yiu P. P., Harden T. J., Cheung M. M. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 1995;39(12):2667–2670.
  2. Ho P.L., Yuen K.Y., Yam W.C., Wong S.Y., Luk W.K. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. J Hosp Infect. 1995;31(4):305–317.
  3. French G.L., Ling J., Ling T., Hui Y.W. Susceptibility of Hong Kong isolates of methicillin-resistant Staphylococcus aureus to antimicrobial agents. J Antimicrob Chemother. 1988;21(5):581–588.
  4. Cheng A.F., French G.L. Methicillin-resistant Staphylococcus aureus bacteraemia in Hong Kong. J Hosp Infect. 1988;12(2):91–101.
  5. Ballow C.H., Schentag J.J. Trends in antibiotic utilization and bacterial resistance. report of the national nosocomial resistance surveillance group. Diagn Microbiol Infect Dis. 1992;15(2 Suppl):37S–42S.
  6. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 1995;44(RR-12):1–13.
  7. Cheng V.C., Wong S.C.Y., Ho P.L., Yuen K.Y. Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China. Emerg Microbes Infect. 2015;4(2):e8.
  8. Cannavino C.R., Mendes R.E., Sader H.S., Farrell D.J., Critchley I.A., Biek D., et al. Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. Pediatr Infect Dis J. 2016;35(7):813–815.
  9. Long S.W., Olsen R.J., Mehta S.C., Palzkill T., Cernoch P.L., Perez K.K., et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2014;58(11):6668–6674.
  10. Centers for Disease Control and Prevention. USA MRSA infections: Diagnosis & testing of MRSA. 2012.
  11. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292.
  12. Corey G.R. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis. 2009;48 Suppl 4:S254-259.
  13. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60(4):788–794.
  14. Wang G., Hindler J.F., Ward K.W., Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44(11):3883–3886.
  15. Ho P.L., Lo P.Y., Chow K.H., Lau E.H., Lai E.L., Cheng V.C., et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect. 2010;60(2):140–145.
  16. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., Moellering R.J. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38(12):1700–1705.
  17. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138–2144.
  18. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315–3320.
  19. Ho P.L., Chow K.H., Lo P.Y., Lee K.F., Lai E.L. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus associated with spread of the ST45 lineage in Hong Kong. Diagn Microbiol Infect Dis. 2009;64(2):131–137.
  20. Luk S., Ho A.Y., Ng T.K., Tsang I.H., Chan E.H., Choi K.W., et al. Prevalence, prediction, and clonality of methicillin-resistant Staphylococcus aureus carriage at admission to medical units in Hong Kong, China. Infect Control Hosp Epidemiol. 2014;35(1):42–48.
  21. Ho P.L., Chuang S.K., Choi Y.F., Lee R.A., Lit A.C., Ng T.K., et al. Community-associated methicillin-resistant and methicillin-sensitive Staphylococcus aureus: skin and soft tissue infections in Hong Kong. Diagn Microbiol Infect Dis. 2008;61(3):245–250.
  22. Ho P.L., Wong M.P., Lai E.L., Chan K.H., Chiu S.S. DNA typing of cytological samples for retrospective identification of an early case of panton-valentine leucocidin-positive, community-associated methicillin-resistant Staphylococcus aureus pneumonia. J Clin Microbiol. 2008;46(7):2457–2458.
  23. Ho P.L., Tse C.W., Mak G.C., Chow K.H., Ng T.K. Community-acquired methicillin-resistant Staphylococcus aureus arrives in Hong Kong. J Antimicrob Chemother. 2004;54(4):845–846.
  24. Tsang S. Review of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection in Hong Kong, 2012-2015. Commun Dis Watch. 2015;12(23).
  25. Centre for Health Protection. Centre for Health Protection - Number of notifiable infectious diseases by month in 2016 [Internet]. 2017 [cited 2017 May 18]. Available from: http://www.chp.gov.hk/en/data/1/10/26/43/5128.html
  26. Leung Y.H., Lai R.W., Chan A.C., Lo J.Y., Ho P.L., Wong M.M., et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infection in Hong Kong. J Infect. 2012;64(5):494–499.
  27. Cheng V.C., Lau Y.K., Lee K.L., Yiu K.H., Chan K.H., Ho P.L., et al. Fatal co-infection with swine origin influenza virus A/H1N1 and community-acquired methicillin-resistant Staphylococcus aureus. J Infect. 2009;59(5):366–370.
  28. Murray R.J., Robinson J.O., White J.N., Hughes F., Coombs G.W., Pearson J.C., et al. Community-acquired pneumonia due to Pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One. 2010;5(1):e8705.
  29. Obando I., Valderrabanos E.S., Millan J.A., Neth O.W. Necrotising pneumonia due to influenza A (H1N1) and community-acquired methicillin-resistant Staphylococcus aureus clone USA300: successful management of the first documented paediatric case. Arch Dis Child. 2010;95(4):305–306.
  30. Arias C.A., Contreras G.A., Murray B.E. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010;16(6):555–562.
  31. Chuang V.W., Tsang D.N., Lam J.K., Lam R.K., Ng W.H. An active surveillance study of vancomycin-resistant Enterococcus in Queen Elizabeth Hospital, Hong Kong. Hong Kong Med J. 2005;11(6):463–471.
  32. Ho P.L., Hong Kong intensive care unit antimicrobial resistance study (HK-ICARE) Group. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant Gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med. 2003;31(4):1175–1182.
  33. Cheng V.C., Tai J.W., Chau P.H., Lai C.K., Chuang V.W., So S.Y., et al. Successful control of emerging vancomycin-resistant enterococci by territory-wide implementation of directly observed hand hygiene in patients in Hong Kong. Am J Infect Control. 2016;44(10):1168–1171.
  34. Willems R.J., Top J., van Santen M., Robinson D.A., Coque T.M., Baquero F., et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis. 2005;11(6):821–828.
  35. Top J., Willems R., Bonten M. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol. 2008;52(3):297–308.
  36. de Regt M.J.A., van der Wagen L.E., Top J., Blok H.E.M., Hopmans T.E.M., Dekker A.W., et al. High acquisition and environmental contamination rates of CC17 ampicillin-resistant Enterococcus faecium in a Dutch hospital. J Antimicrob Chemother. 2008;62(6):1401–1406.
  37. Valdezate S., Labayru C., Navarro A., Mantecón M.A., Ortega M., Coque T.M., et al. Large clonal outbreak of multidrug-resistant CC17 ST17 Enterococcus faecium containing Tn5382 in a Spanish hospital. J Antimicrob Chemother. 2009;63(1):17–20.
  38. Klare I., Konstabel C., Mueller-Bertling S., Werner G., Strommenger B., Kettlitz C., et al. Spread of ampicillin/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur J Clin Microbiol Infect Dis. 2005;24(12):815–825.
  39. Panesso D., Reyes J., Rincón S., Díaz L., Galloway-Peña J., Zurita J., et al. Molecular epidemiology of vancomycin-resistant Enterococcus faecium: a prospective, multicenter study in South American hospitals. J Clin Microbiol. 2010;48(5):1562–1569.
  40. Hsieh Y.C., Lee W.S., Ou T.Y., Hsueh P.R. Clonal spread of CC17 vancomycin-resistant Enterococcus faecium with multilocus sequence type 78 (ST78) and a novel ST444 in Taiwan. Eur J Clin Microbiol Infect Dis. 2010;29(1):25–30.
  41. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–686.
  42. Ho P.L., Poon W.W., Loke S.L., Leung M.S., Chow K.H., Wong R.C., et al. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women. J Antimicrob Chemother. 2007;60(1):140–144.
  43. Ho P.L., Wong R.C., Yip K.S., Loke S.L., Leung M.S., Mak G.C., et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn Microbiol Infect Dis. 2007;59(4):439–445.
  44. Rodríguez-Baño J., Navarro M.D., Romero L., Muniain M.A., Cueto M. de, Ríos M.J., et al. Bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43(11):1407–1414.
  45. Kang C.I., Cheong H.S., Chung D.R., Peck K.R., Song J.H., Oh M.D., et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2008;27(1):85–88.
  46. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Ruíz M., Peña C., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50(1):40–48.
  47. Ben-Ami R., Rodríguez-Baño J., Arslan H., Pitout J.D., Quentin C., Calbo E.S., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682–690.
  48. Rodríguez-Baño J., Lopez-Cerero L., Navarro M.D., Diaz de Alba P., Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother. 2008;62(5):1142–1149.
  49. Ho P.L., Chow K.H., Lai E.L., Lo W.U., Yeung M.K., Chan J., et al. Extensive dissemination of CTX-M-producing Escherichia coli with multidrug resistance to “critically important” antibiotics among food animals in Hong Kong, 2008-10. J Antimicrob Chemother. 2011;66(4):765–768.
  50. Ho P.L., Lo W.U., Yeung M.K., Li Z., Chan J., Chow K.H., et al. Dissemination of pHK01-like incompatibility group IncFII plasmids encoding. Vet Microbiol. 2012;158(1–2):172–179.
  51. Ho P.L., Chau P.H., Yan M.K., Chow K.H., Chen J.H., Wong S.C., et al. High burden of extended-spectrum beta-lactamase-positive Escherichia coli in geriatric patients. J Med Microbiol. 2014;63(Pt 6):878–883.
  52. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-sixth informational supplement. 2016. (M100-S26).
  53. European Society of Clinical Microbiology and Infectious Diseases: Clinical breakpoints [Internet]. 2013 [cited 2017 May 19]. Available from: http://www.eucast.org/clinical_breakpoints/
  54. Livermore D.M., Andrews J.M., Hawkey P.M., Ho P.L., Keness Y., Doi Y., et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67(7):1569–1577.
  55. Ho P.L., Chow K.H., Lo W.U., To K.K., Cheng V.C. Effect of applying the new Clinical and Laboratory Standards Institute ceftazidime and ceftriaxone susceptibility breakpoints for Escherichia coli in Hong Kong. Int J Antimicrob Agents. 2011;37(3):270–271.
  56. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–236.
  57. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–1161.
  58. Queenan A.M., Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–458
  59. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York city: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165(12):1430–1435.
  60. Leavitt A., Navon-Venezia S., Chmelnitsky I., Schwaber M.J., Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother. 2007;51(8):3026–3029.
  61. Cuzon G., Naas T., Demachy M.C., Nordmann P. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother. 2008;52(2):796–797.
  62. Villegas M.V., Lolans K., Correa A., Suarez C.J., Lopez J.A., Vallejo M., et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880–2882.
  63. Pasteran F.G., Otaegui L., Guerriero L., Radice G., Maggiora R., Rapoport M., et al. Klebsiella pneumoniae Carbapenemase-2, Buenos Aires, Argentina. Emerg Infect Dis. 2008;14(7):1178–1180.
  64. Peirano G., Seki L.M., Val Passos V.L., Pinto M.C., Guerra L.R., Asensi M.D. Carbapenem-hydrolysing beta-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil. J Antimicrob Chemother. 2009;63(2):265–268.
  65. Wei Z.Q., Du X.X., Yu Y.S., Shen P., Chen Y.G., Li L.J. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother. 2007;51(2):763–765.
  66. Cai J.C., Zhou H.W., Zhang R., Chen G.X. Emergence of serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother. 2008;52(6):2014–2018.
  67. Borer A., Saidel-Odes L., Riesenberg K., Eskira S., Peled N., Nativ R., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 2009;30(10):972–976.
  68. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046–5054.
  69. Struelens M.J., Monnet D.L., Magiorakos A.P., Santos O’Connor F., Giesecke J., European NDM-1 Survey Participants. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill. 2010;15(46).
  70. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602.
  71. Ho P.L., Lo W.U., Yeung M.K., Lin C.H., Chow K.H., Ang I., et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS One. 2011;6(3):e17989.
  72. Lo J.Y.C. An overview of surveillance of antimicrobial resistance by CHP in Hong Kong. Commun Dis Watch. 2010;7(17).
  73. Ho P.L., Tse C.W., Lai E.L., Lo W.U., Chow K.H. Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Int J Antimicrob Agents. 2011;37(4):386–387.
  74. Abdul Ghafur K. An obituary--on the death of antibiotics! J Assoc Physicians India. 2010;58:143–144.
  75. Ho P.L., Li Z., Lai E.L., Chiu S.S., Cheng V.C.C. Emergence of NDM-1-producing Enterobacteriaceae in China. J Antimicrob Chemother. 2012;67(6):1553–1555.
  76. Chong S. Cases of New Delhi metallo-β-lactamase (NDM) Carbapenemase-producing Enterobacteriaceae in Hong Kong in 2014. Commun Dis Watch. 2015;12(1).
  77. Ho P.L., Cheung Y.Y., Wang Y., Lo W.U., Lai E.L., Chow K.H., et al. Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong Kong. Eur J Clin Microbiol Infect Dis. 2016;35(3):379–385.
  78. Liu Y.Y., Wang Y., Walsh T.R., Yi L.X., Zhang R., Spencer J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
  79. Wong S.C.Y., Tse H., Chen J.H.K., Cheng V.C.C., Ho P.L., Yuen K.Y. Colistin-resistant Enterobacteriaceae carrying the mcr-1 gene among patients in Hong Kong. Emerg Infect Dis. 2016;22(9):1667–1669.
  80. Zheng B., Dong H., Xu H., Lv J., Zhang J., Jiang X., et al. Coexistence of MCR-1 and NDM-1 in clinical Escherichia coli isolates. Clin Infect Dis. 2016;63(10):1393–1395.
  81. Yao X., Doi Y., Zeng L., Lv L., Liu J.H. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect Dis. 2016;16(3):288–289.
  82. Yu H., Qu F., Shan B., Huang B., Jia W., Chen C., et al. Detection of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae from different hospitals in China. Antimicrob Agents Chemother. 2016;60(8):5033–5035.
  83. Delgado-Blas J.F., Ovejero C.M., Abadia-Patino L., Gonzalez-Zorn B. Coexistence of mcr-1 and blaNDM-1 in Escherichia coli from Venezuela. Antimicrob Agents Chemother. 2016;60(10):6356–6358.
  84. Teo J.Q., Ong R.T., Xia E., Koh T.H., Khor C.C., Lee S.J., et al. mcr-1 in multidrug-resistant blaKPC-2-producing clinical Enterobacteriaceae isolates in Singapore. Antimicrob Agents Chemother. 2016;60(10):6435–6437.
  85. Falgenhauer L., Waezsada S.E., Yao Y., Imirzalioglu C., Kasbohrer A., Roesler U., et al. Colistin resistance gene mcr-1 in extended-spectrum beta-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect Dis. 2016;16(3):282–283.
  86. Eliopoulos G.M., Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–1263.
  87. Ho P.L., Ho A.Y., Chow K.H., Cheng V.C. Surveillance for multidrug-resistant Acinetobacter baumannii: a lesson on definitions. Int J Antimicrob Agents. 2010;36(5):469–471.
  88. Angulo F.J., Collignon P., Powers J.H., Chiller T.M., Aidara-Kane A., Aarestrup F.M. World Health Organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies for the use of antimicrobials in food production animals. Clin Infect Dis. 2009;49(1):132–141.
  89. Ho P.L., Ho A.Y., Chow K.H., Lai E.L., Ching P., Seto W.H. Epidemiology and clonality of multidrug-resistant Acinetobacter baumannii from a healthcare region in Hong Kong. J Hosp Infect. 2010;74(4):358–364.
  90. Kwon K.T., Oh W.S., Song J.H., Chang H.H., Jung S.I., Kim S.W., et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007;59(3):525–530.
  91. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–3484.
  92. Fu Y., Zhou J., Zhou H., Yang Q., Wei Z., Yu Y., et al. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. J Antimicrob Chemother. 2010;65(4):644–650.
  93. Wang H., Guo P., Sun H., Wang H., Yang Q., Chen M., et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother. 2007;51(11):4022–4028.
  94. Richet H.M., Mohammed J., McDonald L.C., Jarvis W.R. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis. 2001;7(2):319–322.
  95. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582.
  96. Mugnier P.D., Poirel L., Naas T., Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35–40.
  97. Miriagou V., Cornaglia G., Edelstein M., Galani I., Giske C.G., Gniadkowski M., et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16(2):112–122.
  98. Cheng V.C., Chen J.H., Poon R.W., Lee W.M., So S.Y., Wong S.C., et al. Control of hospital endemicity of multiple-drug-resistant Acinetobacter baumannii ST457 with directly observed hand hygiene. Eur J Clin Microbiol Infect Dis. 2015;34(4):713–718.
  99. Cheng V.C., Chen J.H., So S.Y., Wong S.C., Yan M.K., Chau P.H., et al. Use of fluoroquinolones is the single most important risk factor for the high bacterial load in patients with nasal and gastrointestinal colonization by multidrug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2015;34(12):2359–2366.
  100. Okazaki N., Narita M., Yamada S., Izumikawa K., Umetsu M., Kenri T., et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001;45(8):617–620.
  101. Xin D., Mi Z., Han X., Qin L., Li J., Wei T., et al. Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009;53(5):2158–2159.
  102. Liu Y., Ye X., Zhang H., Xu X., Li W., Zhu D., et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160–2162.
  103. Cao B., Zhao C.J., Yin Y.D., Zhao F., Song S.F., Bai L., et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51(2):189–194.
  104. Zhao F., Liu G., Wu J., Cao B., Tao X., He L., et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57(3):1521–1523.
  105. Wu P.S., Chang L.Y., Lin H.C., Chi H., Hsieh Y.C., Huang Y.C., et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol. 2013;48(9):904–911.
  106. Hsieh Y.C., Tsao K.C., Huang C.G., Tong S., Winchell J.M., Huang Y.C., et al. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J. 2012;31(2):208–209.
  107. Yoo S.J., Kim H.B., Choi S.H., Lee S.O., Kim S.H., Hong S.B., et al. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrob Agents Chemother. 2012;56(12):6393–6396.
  108. Li X., Atkinson T.P., Hagood J., Makris C., Duffy L.B., Waites K.B. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009;28(8):693–696.
  109. Yamada M., Buller R., Bledsoe S., Storch G.A. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J. 2012;31(4):409–411.
  110. Ferguson G.D., Gadsby N.J., Henderson S.S., Hardie A., Kalima P., Morris A.C., et al. Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J Med Microbiol. 2013;62(Pt 12):1876–1882.
  111. Caballero J.D., Campo R., Mafe M.C., Galvez M., Rodriguez-Dominguez M., Canton R., et al. First report of macrolide resistance in a Mycoplasma pneumoniae isolate causing community-acquired pneumonia in Spain. Antimicrob Agents Chemother. 2014;58(2):1265–1266.
  112. Dumke R., von Baum H., Luck P.C., Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2010;16(6):613–616.
  113. To K.K., Chan K.H., Fung Y.F., Yuen K.Y., Ho P.L. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. Eur Respir J. 2010;36(4):969–971.
  114. Lung D.C., Chan Y.H., Kwong L., Que T.L. Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy. Hong Kong Med J. 2011;17(5):407–409.
  115. Chan K.H., To K.K., Chan B.W., Li C.P., Chiu S.S., Yuen K.Y., et al. Comparison of pyrosequencing, sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant Mycoplasma pneumoniae quasispecies in respiratory specimens. J Clin Microbiol. 2013;51(8):2592–2598.
  116. Lung D.C., Yip E.K., Lam D.S., Que T.L. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Pediatr Infect Dis J. 2013;32(12):1396–1399.
  117. Centre for Health Protection. Centre for Health Protection - Detection of Mycoplasma pneumoniae in respiratory specimens in 2016 [Internet]. [cited 2017 May 18]. Available from: http://www.chp.gov.hk/en/data/1/10/641/642/5136.html
  118. Ho P.L., Law P.Y., Chan B.W.K., Wong C.W., To K.K.W., Chiu S.S., et al. Emergence of macrolide-resistant mycoplasma pneumoniae in Hong Kong is linked to increasing macrolide resistance in multilocus variable-number tandem-repeat analysis type 4-5-7-2. J Clin Microbiol. 2015;53(11):3560–3564.
  119. Barlam T.F., Cosgrove S.E., Abbo L.M., MacDougall C., Schuetz A.N., Septimus E.J., et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77.
  120. Ho P.L., Cheng J.C.F., Ching P.T.Y., Kwan J.K.C., Lim W.W.L., Tong W.C.Y., et al. Optimising antimicrobial prescription in hospitals by introducing an antimicrobial stewardship programme in Hong Kong: consensus statement. Hong Kong Med J. 2006;12(2):141–148.
  121. Carling P., Fung T., Killion A., Terrin N., Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699–706.
  122. Borde J.P., Batin N., Rieg S., Feik R., Reimling C., Kern W.V., et al. Adherence to an antibiotic stewardship bundle targeting Staphylococcus aureus blood stream infections at a 200-bed community hospital. Infection. 2014;42(4):713–719.
  123. Valiquette L., Cossette B., Garant M.P., Diab H., Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007;45 Suppl 2:S112-121.
  124. Yong M.K., Buising K.L., Cheng A.C., Thursky K.A. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother. 2010;65(5):1062–1069.
  125. Timbrook T.T., Hurst J.M., Bosso J.A. Impact of an antimicrobial stewardship program on antimicrobial utilization, bacterial susceptibilities, and financial expenditures at an academic medical center. Hosp Pharm. 2016;51(9):703–711.
  126. Ng C.K., Wu T.C., Chan W.M., Leung Y.S., Li C.K., Tsang D.N., et al. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong. Qual Saf Health Care. 2008;17(5):387–392.
  127. Australian Council on Healthcare Standards, Hong Kong (China), Steering Committee on Hospital Accreditation, Hospital Authority (Hong Kong C., Hong Kong Committee on Standards. Section 5 - Standards, criteria, elements and guidelines. Standard 1.5: The organisation provides safe care and services. In: ACHS EQuIP6 Hong Kong Guide. 2016. p. 135.
  128. Centre for Health Protection. Bacterial pathogen isolation and percentage of antimicrobial resistance - out-patient setting [Internet]. [cited 2017 May 22]. Available from: http://www.chp.gov.hk/en/data/1/10/641/697/3345.html
  129. Scott J.G., Cohen D., DiCicco-Bloom B., Orzano A.J., Jaen C.R., Crabtree B.F. Antibiotic use in acute respiratory infections and the ways patients pressure physicians for a prescription. J Fam Pract. 2001;50(10):853–858.
  130. Wun Y.T., Lam T.P., Lam K.F., Ho P.L., Yung W.H. The public’s perspectives on antibiotic resistance and abuse among Chinese in Hong Kong. Pharmacoepidemiol Drug Saf. 2013;22(3):241–249.
  131. Public Health England Managing common infections: guidance for primary care, 2017 update. In p. 1–82.
  132. Rice L.B. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis. 2008;46(4):491–496.
  133. Mangione-Smith R., McGlynn E.A., Elliott M.N., Krogstad P., Brook R.H. The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior. Pediatrics. 1999;103(4 Pt 1):711–718.
  134. Sanchez G.V., Fleming-Dutra K.E., Roberts R.M., Hicks L.A. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep. 2016;65(6):1–12.
  135. Kumana C.R., Ching T.Y., Kong Y., Ma E.C., Kou M., Lee R.A., et al. Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant Staphylococcus aureus infections. Br J Clin Pharmacol. 2001;52(4):427–432.
  136. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control. 1995;23(2):87–94.
  137. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.
  138. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498; quiz 499.
  139. Wilson W., Taubert K.A., Gewitz M., Lockhart P.B., Baddour L.M., Levison M., et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–1754.
  140. Nishimura R.A., Carabello B.A., Faxon D.P., Freed M.D., Lytle B.W., O’Gara P.T., et al. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(8):676–685.
  141. Finkelstein R., Rabino G., Mashiah T., Bar-El Y., Adler Z., Kertzman V., et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant Staphylococcal infections. J Thorac Cardiovasc Surg. 2002;123(2):326–332.
  142. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-93.
  143. Gilbert D., Chambers H., Eliopoulos G., Saag M. The Sanford guide to antimicrobial therapy 2015.
  144. Bennett W.M., Aronoff G.R., Morrison G., Golper T.A., Pulliam J., Wolfson M., et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis.1983;3(3):155–193.
  145. Patel N., Pai M.P., Rodvold K.A., Lomaestro B., Drusano G.L., Lodise T.P.Vancomycin: we can’t get there from here. Clin Infect Dis. 2011;52(8):969–974.
  146. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R.J., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98.
  147. Ye Z.K., Chen Y.L., Chen K., Zhang X.L., Du G.H., He B., et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother.2016;71(11):3020–3025.
  148. Ho P.L., Ng T.K., Yung R.W., Que T.L., Yip E.K., Tse C.W., et al. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong. J Antimicrob Chemother. 2001;48(4):590–592.
  149. Wu V.C., Wang Y.T., Wang C.Y., Tsai I.J., Wu K.D., Hwang J.J., et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72.
  150. De Vriese A.S., Coster R.V., Smet J., Seneca S., Lovering A., Van Haute L.L., et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111–1117.
  151. Lawrence K.R., Adra M., Gillman P.K. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42(11):1578–1583.
  152. Postmarket Drug Safety Information for Patients and Providers. FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin) [Internet]. [cited 2017 May 22]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm220273.htm
  153. Olson M.W., Ruzin A., Feyfant E., Rush T. 3rd, O’Connell J., Bradford P.A. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006;50(6):2156–2166.
  154. Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections [Internet]. 2010 [cited 2017 May 22]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm224370.htm
  155. Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning [Internet]. 2013 [cited 2017 May 22]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm369580.htm
  156. Kwa A.L., Falagas M.E., Michalopoulos A., Tam V.H. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis. 2011;52(10):1278-1279; author reply 1279-1280.
  157. Nation R.L., Li J., Cars O., Couet W., Dudley M.N., Kaye K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the prato polymyxin consensus. Lancet Infect Dis. 2015;15(2):225–234.
  158. Morrill H.J., Pogue J.M., Kaye K.S., LaPlante K.L. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2015;2(2):ofv050.
  159. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50.
  160. Falagas M.E., Vouloumanou E.K., Samonis G., Vardakas K.Z. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
  161. Vardakas K.Z., Legakis N.J., Triarides N., Falagas M.E. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269–285.
  162. Stankowicz M.S., Ibrahim J., Brown D.L. Once-daily aminoglycoside dosing: an update on current literature. Am J Health Syst Pharm. 2015;72(16):1357–1364.
  163. Kumana C.R., Yuen K.Y. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs. 1994;47(6):902–913.
  164. Paul M., Lador A., Grozinsky-Glasberg S., Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;(1):CD003344.
  165. Paul M., Benuri-Silbiger I., Soares-Weiser K., Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668.
  166. Baddour L.M., Wilson W.R., Bayer A.S., Fowler V.J., Tleyjeh I.M., Rybak M.J., et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–1486.
  167. Burgess D.S. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis. 2005;40 Suppl 2:S99-104.
  168. Biek D., Critchley I.A., Riccobene T.A., Thye D.A. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother. 2010;65 Suppl 4:iv9-16.
  169. Espinel-Ingroff A., Boyle K., Sheehan D.J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150(3):101–115.
  170. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.J., Calandra T.F., Edwards J.J., et al. Clinical practice guidelines for the management of Candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–535.
  171. Cuenca-Estrella M., Rodriguez D., Almirante B., Morgan J., Planes A.M., Almela M., et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother. 2005;55(2):194–199.
  172. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive Candidiasis. N Engl J Med. 2002;347(25):2020–2029.
  173. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive Aspergillosis. N Engl J Med. 2002;347(6):408–415.
  174. Vazquez J.A. Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005;27(6):657–673.
  175. Carver P.L. Micafungin. Ann Pharmacother. 2004;38(10):1707–1721.
  176. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., Alexander B.D. Breakthrough invasive Candidiasis in patients on micafungin. J Clin Microbiol. 2010;48(7):2373–2380.
  177. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of Candidemia and other forms of invasive Candidiasis. Clin Infect Dis. 2007;45(7):883–893.
  178. Raad I.I., Graybill J.R., Bustamante A.B., Cornely O.A., Gaona-Flores V., Afif C., et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726–1734.
  179. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–360.
  180. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.
  181. Patterson T.F., Thompson G. 3rd, Denning D.W., Fishman J.A., Hadley S., Herbrecht R., et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.
  182. Vehreschild J.J., Bohme A., Buchheidt D., Arenz D., Harnischmacher U., Heussel C.P., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55(5):445–449.
  183. Kubiak D.W., Bryar J.M., McDonnell A.M., Delgado-Flores J.O., Mui E., Baden L.R., et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32(4):637–648.
  184. Raad I.I., Hanna H.A., Boktour M., Jiang Y., Torres H.A., Afif C., et al. Novel antifungal agents as salvage therapy for invasive Aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia. 2008;22(3):496–503.
  185. Mohamed W.A., Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive Candidiasis in newborn infants. J Trop Pediatr. 2012;58(1):25–30.
  186. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of Candidal esophagitis. Clin Infect Dis. 2001;33(9):1529–1535.
  187. Arathoon E.G., Gotuzzo E., Noriega L.M., Berman R.S., DiNubile M.J., Sable C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 2002;46(2):451–457.
  188. Hiramatsu Y., Maeda Y., Fujii N., Saito T., Nawa Y., Hara M., et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2008;88(5):588–595.
  189. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416.
  190. Saliba F., Pascher A., Cointault O., Laterre P.F., Cervera C., De Waele J.J., et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015;60(7):997–1006.
  191. Maertens J.A., Madero L., Reilly A.F., Lehrnbecher T., Groll A.H., Jafri H.S., et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29(5):415–420.
  192. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 Sep 30;351(14):1391-1402.
  193. Herbrecht R., Patterson T.F., Slavin M.A., Marchetti O., Maertens J., Johnson E.M., et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis. 2015;60(5):713–720.
  194. Betts R.F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R.J., et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive Candidiasis. Clin Infect Dis. 2009;48(12):1676–1684.
  195. Villanueva A., Gotuzzo E., Arathoon E.G., Noriega L.M., Kartsonis N.A., Lupinacci R.J., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal Candidiasis. Am J Med. 2002;113(4):294–299.
  196. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705–713.
  197. Ito Y., Ohyashiki K., Yoshida I., Takeuchi M., Aoyama Y., Mugitani A., et al. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. Int J Hematol. 2007;85(2):121–127.
  198. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225-234.
  199. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–1297.
  200. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive Candidiasis. N Engl J Med. 2007;356(24):2472–2482.
  201. Kett D.H., Shorr A.F., Reboli A.C., Reisman A.L., Biswas P., Schlamm H.T. Anidulafungin compared with fluconazole in severely ill patients with Candidemia and other forms of invasive Candidiasis: support for the 2009 IDSA treatment guidelines for Candidiasis. Crit Care. 2011;15(5):R253.
  202. Krause D.S., Simjee A.E., van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal Candidiasis. Clin Infect Dis. 2004;39(6):770–775.
  203. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
  204. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347.
  205. Sanchez-Ortega I., Patino B., Arnan M., Peralta T., Parody R., Gudiol C., et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2011;46(5):733–739.
  206. Boogaerts M., Winston D.J., Bow E.J., Garber G., Reboli A.C., Schwarer A.P., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135(6):412–422.
  207. Park S.H., Choi S.M., Lee D.G., Choi J.H., Yoo J.H., Min W.S., et al. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. Korean J Intern Med. 2006;21(3):165–172.
  208. Maertens J.A., Raad I.I., Marr K.A., Patterson T.F., Kontoyiannis D.P., Cornely O.A., et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
  209. de Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal Candidiasis in. Clin Infect Dis. 2004;39(6):842–849.
  210. de Wet N.T., Bester A.J., Viljoen J.J., Filho F., Suleiman J.M., Ticona E., et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal Candidiasis. Aliment Pharmacol Ther. 2005;21(7):899–907.
  211. Ananda-Rajah M.R., Grigg A., Downey M.T., Bajel A., Spelman T., Cheng A., et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97(3):459–463.
  212. Marks D.I., Pagliuca A., Kibbler C.C., Glasmacher A., Heussel C.P., Kantecki M., et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–327.
  213. Wingard J.R., Carter S.L., Walsh T.J., Kurtzberg J., Small T.N., Baden L.R., et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–5118.
  214. Prentice H.G., Hann I.M., Herbrecht R., Aoun M., Kvaloy S., Catovsky D., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711–718.
  215. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31(5):1155–1163.
  216. Marr K.A., Schlamm H.T., Herbrecht R., Rottinghaus S.T., Bow E.J., Cornely O.A., et al. Combination antifungal therapy for invasive Aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89.
  217. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for Candidaemia and invasive Candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–1527.
  218. Queiroz-Telles F., Berezin E., Leverger G., Freire A., van der Vyver A., Chotpitayasunondh T., et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive Candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820–826.
  219. Dupont B.F., Lortholary O., Ostrosky-Zeichner L., Stucker F., Yeldandi V. Treatment of Candidemia and invasive Candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13(5):R159.
  220. Ally R., Schurmann D., Kreisel W., Carosi G., Aguirrebengoa K., Dupont B., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal Candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33(9):1447–1454.
  221. Rijnders B.J., Cornelissen J.J., Slobbe L., Becker M.J., Doorduijn J.K., Hop W.C., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary Aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401–1408.
  222. Jeong S.H., Kim D.Y., Jang J.H., Mun Y.C., Choi C.W., Kim S.H., et al. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. Ann Hematol. 2016;95(2):337–344.
  223. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for Candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–1442.
  224. Viljoen J., Azie N., Schmitt-Hoffmann A.H., Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal Candidiasis. Antimicrob Agents Chemother. 2015;59(3):1671–1679.
  225. Mandhaniya S., Swaroop C., Thulkar S., Vishnubhatla S., Kabra S.K., Xess I., et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol. 2011;33(8):e333-341.
  226. Maschmeyer G., Heinz W.J., Hertenstein B., Horst H.A., Requadt C., Wagner T., et al. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur J Clin Microbiol Infect Dis. 2013;32(5):679–689.
  227. Shang W., Feng G., Sun R., Wang X., Liu W., Zhang S., et al. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients. J Clin Pharm Ther. 2012;37(6):652–656.
  228. Winston D.J., Limaye A.P., Pelletier S., Safdar N., Morris M.I., Meneses K., et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758–2764.
  229. Knitsch W., Vincent J.L., Utzolino S., Francois B., Dinya T., Dimopoulos G., et al. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive Candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis. 2015;61(11):1671–1678.
  230. Ostrosky-Zeichner L., Shoham S., Vazquez J., Reboli A., Betts R., Barron M.A., et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive Candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219–1226.
  231. Kohno S., Izumikawa K., Yoshida M., Takesue Y., Oka S., Kamei K., et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of Candidiasis and Aspergillosis. Eur J Clin Microbiol Infect Dis. 2013;32(3):387–397.
  232. Ross J.J., Davidson L. Methicillin-resistant Staphylococcus aureus septic arthritis: an emerging clinical syndrome. Rheumatology. 2005;44(9):1197–1198.
  233. Lin W.T., Wu C.D., Cheng S.C., Chiu C.C., Tseng C.C., Chan H.T., et al. High prevalence of methicillin-resistant Staphylococcus aureus among patients with septic arthritis caused by Staphylococcus aureus. PLoS One. 2015;10(5):e0127150.
  234. Sharff K.A., Richards E.P., Townes J.M. Clinical management of septic arthritis. Curr Rheumatol Rep. 2013;15(6):332.
  235. Berbari E.F., Kanj S.S., Kowalski T.J., Darouiche R.O., Widmer A.F., Schmitt S.K., et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-46.
  236. Nguyen H.M., Graber C.J. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother. 2010;65(1):24–36.
  237. Lipsky B.A., Berendt A.R., Cornia P.B., Pile J.C., Peters E.J.G., Armstrong D.G., et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-173.
  238. Selva Olid A., Sola I., Barajas-Nava L.A., Gianneo O.D., Bonfill Cosp X., Lipsky B.A. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev. 2015;(9):CD009061.
  239. Grayson M.L., Gibbons G.W., Habershaw G.M., Freeman D.V., Pomposelli F.B., Rosenblum B.I., et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18(5):683–693.
  240. Schaper N.C., Dryden M., Kujath P., Nathwani D., Arvis P., Reimnitz P., et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013;41(1):175–186.
  241. Xu Z.R., Ran X.W., Xian Y., Yan X.D., Yuan G.Y., Mu S.M., et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. J Antimicrob Chemother. 2016;71(6):1688–1696.
  242. Stevens D.L., Bisno A.L., Chambers H.F., Dellinger E.P., Goldstein E.J., Gorbach S.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.
  243. Centre for Health Protection. Empirical antibiotic treatment of scarlet fever due to Group A Streptococcus [Internet]. 2011. Available from: http://www.chp.gov.hk/files/pdf/ltd_treatment_of_gas_20110613.pdf
  244. Davies M.R., Holden M.T., Coupland P., Chen J.H.K., Venturini C., Barnett T.C., et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat Genet. 2015;47(1):84–87.
  245. Tang W.M., Ho P.L., Fung K.K., Yuen K.Y., Leong J.C. Necrotising fasciitis of a limb. J Bone Joint Surg Br. 2001;83(5):709–714.
  246. Sartelli M., Malangoni M.A., May A.K., Viale P., Kao L.S., Catena F., et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg WJES. 2014;9(1):57.
  247. Lappin E., Ferguson A.J. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9(5):281–290.
  248. Kaul R., McGeer A., Norrby-Teglund A., Kotb M., Schwartz B., O’Rourke K., et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999;28(4):800–807.
  249. Darenberg J., Ihendyane N., Sjölin J., Aufwerber E., Haidl S., Follin P., et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333–340.
  250. Linner A., Darenberg J., Sjolin J., Henriques-Normark B., Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with Streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59(6):851–857.
  251. Carapetis J.R., Jacoby P., Carville K., Ang S.J., Curtis N., Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A Streptococcal infections. Clin Infect Dis. 2014;59(3):358–365.
  252. Minami M., Kamimura T., Isaka M., Tatsuno I., Ohta M., Hasegawa T. Clindamycin-induced covS-mediated regulation of the production of virulent exoproteins streptolysin O, NAD glycohydrolase, and streptokinase in Streptococcus pyogenes. Antimicrob Agents Chemother. 2010;54(1):98–102.
  253. Andreoni F., Zurcher C., Tarnutzer A., Schilcher K., Neff A., Keller N., et al. Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome. J Infect Dis. 2017;215(2):269–277.
  254. Tanaka M., Hasegawa T., Okamoto A., Torii K., Ohta M. Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob Agents Chemother. 2005;49(1):88–96.
  255. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164.
  256. Fleisher G.R. The management of bite wounds. N Engl J Med. 1999;340(2):138–140.
  257. Ellis R., Ellis C. Dog and cat bites. Am Fam Physician. 2014;90(4):239–243.
  258. Dendle C., Looke D. Review article: animal bites: an update for management with a focus on infections. Emerg Med Australas. 2008;20(6):458–467.
  259. Boyanova L., Kolarov R., Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015;31:4–10.
  260. Brouwer M.C., Coutinho J.M., van de Beek D. Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis. Neurology. 2014;82(9):806–813.
  261. Brouwer M.C., Tunkel A.R., McKhann G. 2nd, van de Beek D. Brain abscess. N Engl J Med. 2014;371(5):447–456.
  262. Cannon J.P., Lee T.A., Clark N.M., Setlak P., Grim S.A. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014;69(8):2043–2055.
  263. Tunkel A.R., Hartman B.J., Kaplan S.L., Kaufman B.A., Roos K.L., Scheld W.M., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–1284.
  264. McGill F., Heyderman R.S., Michael B.D., Defres S., Beeching N.J., Borrow R., et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. J Infect. 2016;72(4):405–438.
  265. van de Beek D., Cabellos C., Dzupova O., Esposito S., Klein M., Kloek A.T., et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62.
  266. Elyasi S., Khalili H., Dashti-Khavidaki S., Emadi-Koochak H. Conventional- versus high-dose vancomycin regimen in patients with acute bacterial meningitis: a randomized clinical trial. Expert Opin Pharmacother. 2015;16(3):297–304.
  267. Brouwer M.C., McIntyre P., Prasad K., van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;(9):CD004405.
  268. van Samkar A., Brouwer M.C., Schultsz C., van der Ende A., van de Beek D. Streptococcus suis meningitis: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9(10):e0004191.
  269. Hsueh P.R. Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010. Int J Antimicrob Agents. 2012;40 Suppl:S1-3.
  270. Liu Y.M., Chen Y.S., Toh H.S., Huang C.C., Lee Y.L., Ho C.M., et al. In vitro susceptibilities of non- Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40 Suppl:S11-17.
  271. Sartelli M., Viale P., Catena F., Ansaloni L., Moore E., Malangoni M., et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg WJES. 2013;8(1):3.
  272. Montravers P., Dupont H., Leone M., Constantin J.M., Mertes P.M., Laterre P.F., et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34(2):117–130.
  273. Gomi H., Solomkin J.S., Takada T., Strasberg S.M., Pitt H.A., Yoshida M., et al. TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):60–70.
  274. Chiu C.T., Lin D.Y., Liaw Y.F. Metastatic septic endophthalmitis in pyogenic liver abscess. J Clin Gastroenterol. 1988;10(5):524–527.
  275. Fang C.T., Lai S.Y., Yi W.C., Hsueh P.R., Liu K.L., Chang S.C. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis. 2007;45(3):284–293.
  276. Fung C.P., Chang F.Y., Lee S.C., Hu B.S., Kuo B.I., Liu C.Y., et al. A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Gut. 2002;50(3):420–424.
  277. Lee S.S., Chen Y.S., Tsai H.C., Wann S.R., Lin H.H., Huang C.K., et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess. Clin Infect Dis. 2008;47(5):642–650.
  278. Sheu S.J., Kung Y.H., Wu T.T., Chang F.P., Horng Y.H. Risk factors for endogenous endophthalmitis secondary to Klebsiella pneumoniae liver abscess: 20-year experience in Southern Taiwan. Retina. 2011;31(10):2026–2031.
  279. Sng C.C., Jap A., Chan Y.H., Chee S.P. Risk factors for endogenous Klebsiella endophthalmitis in patients with Klebsiella bacteraemia: a case-control study. Br J Ophthalmol. 2008;92(5):673–677.
  280. Lee J.Y., Kim K.H. Endogenous endophthalmitis complicated by pyogenic liver abscess: a review of 17 years’ experience at a single center. Digestion. 2014;90(2):116–121.
  281. Farthing M., Salam M.A., Lindberg G., Dite P., Khalif I., Salazar-Lindo E., et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47(1):12–20.
  282. DuPont H.L. Acute infectious diarrhea in immunocompetent adults. N Engl J Med. 2014;370(16):1532–1540.
  283. Barr W., Smith A. Acute diarrhea. Am Fam Physician. 2014;89(3):180–189.
  284. Zollner-Schwetz I., Krause R. Therapy of acute gastroenteritis: role of antibiotics. Clin Microbiol Infect. 2015;21(8):744–749.
  285. Riddle M.S., DuPont H.L., Connor B.A. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016;111(5):602–622.
  286. Steffen R., Hill D.R., DuPont H.L. Traveler’s diarrhea: a clinical review. JAMA. 2015;313(1):71–80.
  287. Giddings S.L., Stevens A.M., Leung D.T. Traveler’s diarrhea. Med Clin North Am. 2016;100(2):317–330.
  288. Berbari E.F., Cockerill F. 3rd, Steckelberg J.M. Infective endocarditis due to unusual or fastidious microorganisms. Mayo Clin Proc. 1997;72(6):532–542.
  289. Gould F.K., Denning D.W., Elliott T.S., Foweraker J., Perry J.D., Prendergast B.D., et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012;67(2):269–289.
  290. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(23):2440–2492.
  291. Hoen B., Duval X. Infective endocarditis. N Engl J Med. 2013;368(15):1425–1433.
  292. Cahill T.J., Prendergast B.D. Infective endocarditis. Lancet. 2016;387(10021):882–893.
  293. Habib G., Lancellotti P., Antunes M.J., Bongiorni M.G., Casalta J.P., Del Zotti F., et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology (ESC). endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–3128.
  294. Haldar S.M., O’Gara P.T. Infective endocarditis: diagnosis and management. Nat Clin Pract Cardiovasc Med. 2006;3(6):310–317.
  295. Brunham R.C., Gottlieb S.L., Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015;372(21):2039–2048.
  296. Duarte R., Fuhrich D., Ross J.D. A review of antibiotic therapy for pelvic inflammatory disease. Int J Antimicrob Agents. 2015;46(3):272–277.
  297. Ross J., Judlin P., Jensen J. 2012 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2014;25(1):1–7.
  298. Workowski K.A., Bolan G.A. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137.
  299. Dowell D., Kirkcaldy R.D. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect. 2012;88(8):589–594.
  300. Walker C.K., Workowski K.A., Washington A.E., Soper D., Sweet R.L. Anaerobes in pelvic inflammatory disease: implications for the centers for disease control and prevention’s guidelines for treatment of sexually transmitted diseases. Clin Infect Dis. 1999;28 Suppl 1:S29-36.
  301. Lo J.Y., Ho K.M., Lo A.C. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J Antimicrob Chemother. 2012;67(6):1422–1426.
  302. Ho P.L. The best of times, the worst of times, and emerging gonococcal multidrug resistance. Hong Kong J Dermatol Venereol. 2011;19(4):163–166.
  303. Dixon J.M. Breast infection. BMJ. 2013;347:f3291.
  304. Lam E., Chan T., Wiseman S.M. Breast abscess: evidence based management recommendations. Expert Rev Anti Infect Ther. 2014;12(7):753–762.
  305. Amir L.H. ABM clinical protocol #4: mastitis, revised March 2014. Breastfeed Med. 2014;9(5):239–243.
  306. Jaworsky D., Reynolds S., Chow A.W. Extracranial head and neck infections. Crit Care Clin. 2013;29(3):443–463.
  307. Yang W., Hu L., Wang Z., Nie G., Li X., Lin D., et al. Deep neck infection: A review of 130 cases in Southern China. Medicine (Baltimore). 2015;94(27):e994.
  308. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-120.
  309. Grigoryan L., Trautner B.W., Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677–1684.
  310. Drugs for urinary tract infections. JAMA. 2014;311(8):855–856.
  311. Grabe M., Bartoletti R., Bjerklund Johansen T.E., Cai T., Çek M., Köves B., et al. EAU guidelines on urological infections 2015 v2. European Association of Urology 2015. [Internet]. Uroweb. 2015 [cited 2017 Jan 20]. Available from: https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf
  312. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
  313. Center for Drug Evaluation and Research. Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee) - 2015 Meeting Materials, Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee) [Internet]. 2017 [cited 2017 Jan 20]. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm424449.htm
  314. Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together [Internet]. 2016 [cited 2016 Dec 22]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm
  315. Hong Kong Department of Health: Drug Office safety alert on (13 May, 2016). [Internet]. 2016 [cited 2016 Dec 22]. Available from: http://www.drugoffice.gov.hk/eps/news/The_United_States:_FDA_Drug_Safety_Communication:_FDA_advises_restricting_fluoroquinolone_antibiotic/pharmaceutical_trade/2016-05-13/en/26179.html
  316. Jean S.S., Coombs G., Ling T., Balaji V., Rodrigues C., Mikamo H., et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. Int J Antimicrob Agents. 2016;47(4):328–334.
  317. Grossman R.F. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest. 1997;112(6 Suppl):310S–313S.
  318. Schentag J.J., Tillotson G.S. Antibiotic selection and dosing for the treatment of acute exacerbations of COPD. Chest. 1997;112(6 Suppl):314S–319S.
  319. McCrory D.C., Brown C., Gelfand S.E., Bach P.B. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119(4):1190–1209.
  320. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of Chronic Obstructive Lung Disease. 2017.
  321. Ko F.W., Chan K.P., Hui D.S., Goddard J.R., Shaw J.G., Reid D.W., et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152–1165.
  322. McShane P.J., Naureckas E.T., Tino G., Strek M.E. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–656.
  323. Chalmers J.D., Aliberti S., Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446–1462.
  324. Chang A.B., Bell S.C., Torzillo P.J., King P.T., Maguire G.P., Byrnes C.A., et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 2015;202(1):21–23.
  325. DiBardino D.M., Wunderink R.G. Aspiration pneumonia: a review of modern trends. J Crit Care. 2015;30(1):40–48.
  326. National Institute for Health and Care Excellence (NICE). Diagnosis and management of community- and hospital-acquired pneumonia in adults. 2014.
  327. Wunderink R.G., Waterer G.W. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014;370(6):543–551.
  328. Ho P.L., Que T.L., Tsang D.N., Ng T.K., Chow K.H., Seto W.H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 1999;43(5):1310–1313.
  329. Ho P.L., Yam W.C., Que T.L., Tsang D.N., Seto W.H., Ng T.K., et al. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J Antimicrob Chemother. 2001;47(5):655–658.
  330. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
  331. Lim W.S., Baudouin S.V., George R.C., Hill A.T., Jamieson C., Le Jeune I., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1-55.
  332. Levy M.L., Le Jeune I., Woodhead M.A., Macfarlaned J.T., Lim W.S. Primary care summary of the British Thoracic Society guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J. 2010;19(1):21–27.
  333. Lee J.S., Giesler D.L., Gellad W.F., Fine M.J. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: A systematic review. JAMA. 2016;315(6):593–602.
  334. Brown E.M. Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia. J Antimicrob Chemother. 1997;40(4):463–468.
  335. Liapikou A., Rosales-Mayor E., Torres A. Pharmacotherapy for hospital-acquired pneumonia. Expert Opin Pharmacother. 2014;15(6):775–786.
  336. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The working group on severe streptococcal infections. JAMA. 1993;269(3):390–391.
  337. Isenmann R., Rünzi M., Kron M., Kahl S., Kraus D., Jung N., et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology. 2004;126(4):997–1004.
  338. Wu B.U., Banks P.A. Clinical management of patients with acute pancreatitis. Gastroenterology. 2013;144(6):1272–1281.
  339. Howard T.J. The role of antimicrobial therapy in severe acute pancreatitis. Surg Clin North Am. 2013;93(3):585–593.
  340. Lankisch P.G., Apte M., Banks P.A. Acute pancreatitis. Lancet. 2015;386(9988):85–96.
  341. da Costa D.W., Boerma D., van Santvoort H.C., Horvath K.D., Werner J., Carter C.R., et al. Staged multidisciplinary step-up management for necrotizing pancreatitis. Br J Surg. 2014;101(1):e65-79.
  342. Bradley E. 3rd. A clinically based classification system for acute pancreatitis. summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128(5):586–590.
  343. Tenner S., Baillie J., DeWitt J., Vege S.S. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400–1415; 1416.
  344. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1-15.
  345. Isayama H., Nakai Y., Rerknimitr R., Khor C., Lau J., Wang H.P., et al. Asian consensus statements on endoscopic management of walled-off necrosis Part 1: Epidemiology, diagnosis, and treatment. J Gastroenterol Hepatol. 2016;31(9):1546–1554.
  346. Greenberg J.A., Hsu J., Bawazeer M., Marshall J., Friedrich J.O., Nathens A., et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016;59(2):128–140.
  347. Papachristou G.I., Whitcomb D.C. Inflammatory markers of disease severity in acute pancreatitis. Clin Lab Med. 2005;25(1):17–37.
  348. Dervenis C., Johnson C.D., Bassi C., Bradley E., Imrie C.W., McMahon M.J., et al. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol. 1999;25(3):195–210.
  349. Golub R., Siddiqi F., Pohl D. Role of antibiotics in acute pancreatitis: A meta-analysis. J Gastrointest Surg. 1998;2(6):496–503.
  350. Sharma V.K., Howden C.W. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas. 2001;22(1):28–31.
  351. Toouli J., Brooke-Smith M., Bassi C., Carr-Locke D., Telford J., Freeny P., et al. Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol. 2002;17 Suppl:S15-39.
  352. Uhl W., Warshaw A., Imrie C., Bassi C., McKay C.J., Lankisch P.G., et al. IAP guidelines for the surgical management of acute pancreatitis. Pancreatology. 2002;2(6):565–573.
  353. Dellinger E.P., Tellado J.M., Soto N.E., Ashley S.W., Barie P.S., Dugernier T., et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg. 2007;245(5):674–683.
  354. Garcia-Barrasa A., Borobia F.G., Pallares R., Jorba R., Poves I., Busquets J., et al. A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis. J Gastrointest Surg. 2009;13(4):768–774.
  355. Villatoro E., Mulla M., Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev. 2010;(5):CD002941.
  356. Wittau M., Mayer B., Scheele J., Henne-Bruns D., Dellinger E.P., Isenmann R. Systematic review and meta-analysis of antibiotic prophylaxis in severe acute pancreatitis. Scand J Gastroenterol. 2011;46(3):261–270.
  357. Jiang K., Huang W., Yang X.N., Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. World J Gastroenterol. 2012;18(3):279–284.
  358. Lim C.L., Lee W., Liew Y.X., Tang S.S., Chlebicki M.P., Kwa A.L. Role of antibiotic prophylaxis in necrotizing pancreatitis: a meta-analysis. J Gastrointest Surg. 2015;19(3):480–491.
  359. Ukai T., Shikata S., Inoue M., Noguchi Y., Igarashi H., Isaji S., et al. Early prophylactic antibiotics administration for acute necrotizing pancreatitis: a meta-analysis of randomized controlled trials. J Hepatobiliary Pancreat Sci. 2015;22(4):316–321.
  360. Pezzilli R., Zerbi A., Campra D., Capurso G., Golfieri R., Arcidiacono P.G., et al. Consensus guidelines on severe acute pancreatitis. Dig Liver Dis. 2015;47(7):532–543.
  361. Isaji S., Takada T., Mayumi T., Yoshida M., Wada K., Yokoe M., et al. Revised Japanese guidelines for the management of acute pancreatitis 2015: revised concepts and updated points. J Hepatobiliary Pancreat Sci. 2015;22(6):433–445.
  362. Grewe M., Tsiotos G.G., Luque de-Leon E., Sarr M.G. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg. 1999;188(4):408–414.
  363. Gloor B., Muller C.A., Worni M., Stahel P.F., Redaelli C., Uhl W., et al. Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. Arch Surg. 2001;136(5):592–596.
  364. De Waele J.J., Vogelaers D., Blot S., Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis. 2003;37(2):208–213.
  365. Maravi-Poma E., Gener J., Alvarez-Lerma F., Olaechea P., Blanco A., Dominguez-Munoz J.E. Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin. Intensive Care Med. 2003;29(11):1974–1980.
  366. De Waele J.J., Vogelaers D., Hoste E., Blot S., Colardyn F. Emergence of antibiotic resistance in infected pancreatic necrosis. Arch Surg. 2004;139(12):1371–1375.
  367. Berzin T.M., Rocha F.G., Whang E.E., Mortele K.J., Ashley S.W., Banks P.A. Prevalence of primary fungal infections in necrotizing pancreatitis. Pancreatology. 2007;7(1):63–66.
  368. Kochhar R., Ahammed S.K., Chakrabarti A., Ray P., Sinha S.K., Dutta U., et al. Prevalence and outcome of fungal infection in patients with severe acute pancreatitis. J Gastroenterol Hepatol. 2009;24(5):743–747.
  369. De Waele J.J. Use of antibiotics in severe acute pancreatitis. Expert Rev Anti Infect Ther. 2010;8(3):317–324.
  370. Behrman S.W., Bahr M.H., Dickson P.V., Zarzaur B.L. The microbiology of secondary and postoperative pancreatic infections: implications for antimicrobial management. Arch Surg. 2011;146(5):613–619.
  371. Beger H.G., Bittner R., Block S., Buchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology. 1986;91(2):433–438.
  372. Barie P.S. A critical review of antibiotic prophylaxis in severe acute pancreatitis. Am J Surg. 1996;172(6A):38S–43S.
  373. Schubert S., Dalhoff A. Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas. Antimicrob Agents Chemother. 2012;56(12):6434–6436.
  374. Banks P.A., Bollen T.L., Dervenis C., Gooszen H.G., Johnson C.D., Sarr M.G., et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–111.
  375. Holter J.C., Muller F., Bjorang O., Samdal H.H., Marthinsen J.B., Jenum P.A., et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis. 2015;15:64.
  376. Jain S., Self W.H., Wunderink R.G., Fakhran S., Balk R., Bramley A.M., et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–427.
  377. Meehan T.P., Fine M.J., Krumholz H.M., Scinto J.D., Galusha D.H., Mockalis J.T., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278(23):2080–2084.
  378. Houck P.M., Bratzler D.W., Nsa W., Ma A., Bartlett J.G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637–644.
  379. Okada T., Morozumi M., Tajima T., Hasegawa M., Sakata H., Ohnari S., et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55(12):1642–1649.
  380. Bébéar C. Editorial commentary: infections due to macrolide-resistant Mycoplasma pneumoniae: now what? Clin Infect Dis. 2012;55(12):1650–1651.
  381. Kung C.T., Li C.J., Hung S.C., Ko S.F., Chen M.C., Lee C.H., et al. Acute melioid community-acquired pneumonia. Int J Infect Dis. 2011;15(9):e627-630.
  382. Tsang K.W., File T.J. Respiratory infections unique to Asia. Respirology. 2008;13(7):937–949.
  383. Friedland I.R. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14(10):885–890.
  384. Pallares R., Linares J., Vadillo M., Cabellos C., Manresa F., Viladrich P.F., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333(8):474–480.
  385. Metlay J.P., Hofmann J., Cetron M.S., Fine M.J., Farley M.M., Whitney C., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30(3):520–528.
  386. Turett G.S., Blum S., Fazal B.A., Justman J.E., Telzak E.E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis. 1999;29(2):321–327.
  387. Feikin D.R., Schuchat A., Kolczak M., Barrett N.L., Harrison L.H., Lefkowitz L., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90(2):223–229.
  388. Weinstein M.P., Klugman K.P., Jones R.N. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48(11):1596–1600.
  389. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement. 2012. (M100-S22; vol. 32).
  390. Ho P.L., Yung R.W., Tsang D.N., Que T.L., Ho M., Seto W.H., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 2001;48(5):659–665.
  391. Ho P.L., Chiu S.S., Ang I., Lau Y.L. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995-2009. Vaccine. 2011;29(17):3270–3275.
  392. Ho P.L., Chiu S.S., Law P.Y., Chan E.L., Lai E.L., Chow K.H. Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 Streptococcus pneumoniae after introduction of children pneumococcal conjugate vaccination in Hong Kong. Diagn Microbiol Infect Dis. 2015;81(2):145–148.
  393. Liyanapathirana V., Nelson E.A., Ang I., Subramanian R., Ma H., Ip M. Emergence of serogroup 15 Streptococcus pneumoniae of diverse genetic backgrounds following the introduction of pneumococcal conjugate vaccines in Hong Kong. Diagn Microbiol Infect Dis. 2015;81(1):66–70.
  394. Boost M.V., O’Donoghue M.M., Dooley J.S. Prevalence of carriage of antimicrobial resistant strains of Streptococcus pneumoniae in primary school children in Hong Kong. Epidemiol Infect. 2001;127(1):49–55.
  395. Chiu S.S., Ho P.L., Chow F.K., Yuen K.Y., Lau Y.L. Nasopharyngeal carriage of antimicrobial-resistant streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother. 2001;45(10):2765–2770.
  396. Ho P.L., Chiu S.S., Chan M.Y., Ang I., Chow K.H., Lau Y.L. Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong. Diagn Microbiol Infect Dis. 2011;71(4):327–334.
  397. Chan K.C., Subramanian R., Chong P., Nelson E.A., Lam H.S., Li A.M., et al. Pneumococcal carriage in young children after introduction of PCV13 in Hong Kong. Vaccine. 2016;34(33):3867–3874.
  398. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Fifteen informational supplement. 2004. (M100-S15).
  399. Kang C.I., Song J.H., Kim S.H., Chung D.R., Peck K.R., Thamlikitkul V., et al. Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. Infection. 2013;41(1):151–157.
  400. Sterling T.R. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis. 2004;8(12):1396–1400.
  401. Dooley K.E., Golub J., Goes F.S., Merz W.G., Sterling T.R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34(12):1607–1612.
  402. Kang C.I., Song J.H., Kim S.H., Chung D.R., Peck K.R., So T.M., et al. Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study. Eur J Clin Microbiol Infect Dis. 2014;33(1):55–59.
  403. Ho P.L., Tse W.S., Tsang K.W., Kwok T.K., Ng T.K., Cheng V.C., et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32(5):701–707.
  404. Wong S.S., Woo P.C., Luk W.K., Yuen K.Y. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis. 1999;34(1):1–6.
  405. Cheng V.C., Yam W.C., Lam O.T., Tsang J.L., Tse E.Y., Siu G.K., et al. Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis. 2011;30(11):1371–1381.
  406. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415.
  407. Ho P.L., Shek R.H.L., Chow K.H., Duan R.S., Mak G.C., Lai E.L., et al. Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J Antimicrob Chemother. 2005;55(3):326–332.
  408. Lyon D.J., Scheel O., Fung K.S., Cheng A.F., Henrichsen J. Rapid emergence of penicillin-resistant pneumococci in Hong Kong. Scand J Infect Dis. 1996;28(4):375–376.
  409. Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett. 2012;10(122):73-78; quiz 79-80.
  410. Bratzler D.W., Hunt D.R. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis. 2006;43(3):322–330.
  411. How-to Guide: Prevent Surgical Site Infections. Cambridge, MA: Institute for Healthcare Improvement; 2012.
  412. World Health Organization. WHO guidelines on hand hygiene in health care [Internet]. 2009 [cited 2017 May 19]. Available from: http://www.who.int/gpsc/5may/tools/9789241597906/en/
  413. Facility Guidelines Institute. Guidelines for Design and Construction of Hospitals and Outpatient Facilities. 2014.
  414. Great Britain, Department of Health. Specialised ventilation for healthcare premises. Part A, London: TSO; 2007.
  415. Streifel A.J. Design and maintenance of hospital ventilation systems and the prevention of airborne nosocomial infections. In: Hosp Epidemiol Infect Control. Philadelphia: Lippincott Williams & Wilkins; 2004.
  416. An overview of laminar flow ventilation for operating theatres. The Technology Assessment Team, Policy Coordination Unit, Performance Management Branch, Queensland Health, Australia; 1997.
  417. U.S. Army Center for Health Promotion and Preventive Medicine. Guidelines on the Design and Operation of HVAC Systems in Disease Isolation Areas: TG 252. 2000.
  418. Wong E.S. Surgical site infection. In: Hosp Epidemiol Infect Control. Philadelphia: Lippincott Williams & Wilkins; 2004.
  419. National Collaborating Centre for Women’s and Children’s Health (UK). Surgical site infection: Prevention and treatment of surgical site infection. London: RCOG Press; 2008. (National Institute for Health and Clinical Excellence: Guidance).
  420. Fairbanks D.N.F., American Academy of Otolaryngology--Head and Neck Surgery Foundation. Pocket guide to antimicrobial therapy in otolaryngology--head and neck surgery. Alexaneria, VA: American Academy of Otolaryngology--Head & Neck Surgery Foundation, Inc.; 2007.
  421. Chambers H.F., Eliopoulos G.M., Gilbert D.N., Saag M.S. The Sanford guide to antimicrobial therapy 2016.
  422. The care of women requesting induced abortion (evidence-based clinical guideline no.7) [Internet]. Royal college of obstetricians & gynaecologists. [cited 2017 May 23]. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/the-care-of-women-requesting-induced-abortion/
  423. Anderson, D.J., Sexton, D.J. Antimicrobial prophylaxis for prevention of surgical site infection in adults. Uptodate. Jan 2017. [Internet]. 2017 [cited 2017 Jan 20]. Available from: https://www.uptodate.com/contents/antimicrobial-prophylaxis-for-prevention-of-surgical-site-infection-in-adults
  424. Meakins, J.L., Masterson, B.J. Prevention of Postoperative infection. In: ACS Surg
  425. Delgado-Rodriguez M., Bueno-Cavanillas A., Lopez-Gigosos R., de Dios Luna-Castillo J., Guillen-Solvas J., Moreno-Abril O., et al. Hospital stay length as an effect modifier of other risk factors for nosocomial infection. Eur J Epidemiol. 1990;6(1):34–39.
  426. Lidwell O.M., Lowbury E.J., Whyte W., Blowers R., Stanley S.J., Lowe D. Infection and sepsis after operations for total hip or knee-joint replacement: influence of ultraclean air, prophylactic antibiotics and other factors. J Hyg (Lond). 1984;93(3):505–529.
  427. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485.
  428. Aly R., Maibach H.I. Comparative study on the antimicrobial effect of 0.5% chlorhexidine gluconate and 70% isopropyl alcohol on the normal flora of hands. Appl Environ Microbiol. 1979;37(3):610–613.
  429. Brady L.M., Thomson M., Palmer M.A., Harkness J.L. Successful control of endemic MRSA in a cardiothoracic surgical unit. Med J Aust. 1990;152(5):240–245.
  430. Holloway P.M., Platt J.H., Reybrouck G., Lilly H.A., Mehtar S., Drabu Y. A multi-centre evaluation of two chlorhexidine-containing formulations for surgical hand disinfection. J Hosp Infect. 1990;16(2):151–159.
  431. Holtom P.D. Antibiotic prophylaxis: current recommendations. J Am Acad Orthop Surg. 2006;14(10 Spec No.):S98-100.
  432. Kobayashi H. Evaluation of surgical scrubbing. J Hosp Infect. 1991;18 Suppl B:29–34.
  433. Lowbury E.J., Lilly H.A., Ayliffe G.A. Preoperative disinfection of surgeons’ hands: use of alcoholic solutions and effects of gloves on skin flora. Br Med J. 1974;4(5941):369–372.
  434. Nichols R.L. Preventing surgical site infections: a surgeon’s perspective. Emerg Infect Dis. 2001;7(2):220–224.
  435. Rotter M.L., Koller W. Surgical hand disinfection: effect of sequential use of two chlorhexidine preparations. J Hosp Infect. 1990;16(2):161–166.
  436. Tuffnell D.J., Croton R.S., Hemingway D.M., Hartley M.N., Wake P.N., Garvey R.J. Methicillin resistant Staphylococcus aureus; the role of antisepsis in the control of an outbreak. J Hosp Infect. 1987;10(3):255–259.
  437. Wade J.J., Casewell M.W. The evaluation of residual antimicrobial activity on hands and its clinical relevance. J Hosp Infect. 1991;18 Suppl B:23–28.
  438. ACOG practice bulletin No. 120: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011;117(6):1472–1483.
  439. Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16(5):283–293.
  440. Koc M., Zulfikaroglu B., Kece C., Ozalp N. A prospective randomized study of prophylactic antibiotics in elective laparoscopic cholecystectomy. Surg Endosc. 2003;17(11):1716–1718.
  441. Bratzler D.W., Houck P.M. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005;189(4):395–404.
  442. Lynch W., Davey P.G., Malek M., Byrne D.J., Napier A. Cost-effectiveness analysis of the use of chlorhexidine detergent in preoperative whole-body disinfection in wound infection prophylaxis. J Hosp Infect. 1992;21(3):179–191.
  443. Leigh D.A., Stronge J.L., Marriner J., Sedgwick J. Total body bathing with “Hibiscrub” (chlorhexidine) in surgical patients: a controlled trial. J Hosp Infect. 1983;4(3):229–235.
  444. Rotter M.L., Larsen S.O., Cooke E.M., Dankert J., Daschner F., Greco D., et al. A comparison of the effects of preoperative whole-body bathing with detergent alone and with detergent containing chlorhexidine gluconate on the frequency of wound infections after clean surgery. The European working party on control of hospital infections. J Hosp Infect. 1988;11(4):310–320.
  445. Woodhead K., Taylor E.W., Bannister G., Chesworth T., Hoffman P., Humphreys H. Behaviours and rituals in the operating theatre. A report from the Hospital Infection Society Working Party on Infection Control in Operating Theatres. J Hosp Infect. 2002;51(4):241–255.
  446. Avato J.L., Lai K.K. Impact of postdischarge surveillance on surgical-site infection rates for coronary artery bypass procedures. Infect Control Hosp Epidemiol. 2002;23(7):364–367.
  447. Wilson A.P.R., Hodgson B., Liu M., Plummer D., Taylor I., Roberts J., et al. Reduction in wound infection rates by wound surveillance with postdischarge follow-up and feedback. Br J Surg. 2006;93(5):630–638.
  448. Morikane K., Nishioka M., Tanimura H., Noguchi H., Konishi T., Kobayashi H. Using surveillance data to direct infection control efforts to reduce surgical-site infections following clean abdominal operations in Japan. Infect Control Hosp Epidemiol. 2002;23(7):404–406.
  449. Smyth E.T., Emmerson A.M. Surgical site infection surveillance. J Hosp Infect. 2000;45(3):173–184.
  450. Chrintz H., Vibits H., Cordtz T.O., Harreby J.S., Waaddegaard P., Larsen S.O. Need for surgical wound dressing. Br J Surg. 1989;76(2):204–205.
  451. Weiss Y. Simplified management of operative wounds by early exposure. Int Surg. 1983;68(3):237–240.
  452. Smilanich R.P., Bonnet I., Kirkpatrick J.R. Contaminated wounds: the effect of initial management on outcome. Am Surg. 1995;61(5):427–430.
  453. Leonard Y., Speroni K.G., Atherton M., Corriher J. Evaluating use of flash sterilization in the OR with regard to postoperative infections. AORN J. 2006;83(3):672–680.
  454. Rutala W.A. APIC guideline for selection and use of disinfectants. 1994, 1995, and 1996 APIC Guidelines Committee. Association for Professionals in Infection Control and Epidemiology, Inc. Am J Infect Control. 1996;24(4):313–342.
  455. Ayliffe G. Decontamination of minimally invasive surgical endoscopes and accessories. J Hosp Infect. 2000;45(4):263–277.
  456. Rutala W.A., Gergen M.F., Jones J.F., Weber D.J. Levels of microbial contamination on surgical instruments. Am J Infect Control. 1998;26(2):143–145.
  457. Tanner J., Parkinson H. Double gloving to reduce surgical cross-infection. Cochrane Database Syst Rev. 2002;(3):CD003087.
  458. Landrin A., Bissery A., Kac G. Monitoring air sampling in operating theatres: can particle counting replace microbiological sampling? J Hosp Infect. 2005;61(1):27–29.
  459. Jensen P.A., Lambert L.A., Iademarco M.F., Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1–141.
  460. Dharan S., Pittet D. Environmental controls in operating theatres. J Hosp Infect. 2002;51(2):79–84.
  461. Hoffman P.N., Williams J., Stacey A., Bennett A.M., Ridgway G.L., Dobson C., et al. Microbiological commissioning and monitoring of operating theatre suites. England; 2002 Sep p. 1–28.
  462. Lidwell O.M., Elson R.A., Lowbury E.J., Whyte W., Blowers R., Stanley S.J., et al. Ultraclean air and antibiotics for prevention of postoperative infection. A multicenter study of 8,052 joint replacement operations. Acta Orthop Scand. 1987;58(1):4–13.
  463. Chow T.T., Yang X.Y. Ventilation performance in operating theatres against airborne infection: review of research activities and practical guidance. J Hosp Infect. 2004;56(2):85–92.
  464. Humphreys H., Taylor E.W. Operating theatre ventilation standards and the risk of postoperative infection. J Hosp Infect. 2002;50(2):85–90.
  465. Sehulster L., Chinn R.Y.W., CDC, HICPAC. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-10):1–42.
  466. Higgins A., London J., Charland S., Ratzer E., Clark J., Haun W., et al. Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary? Arch Surg. 1999;134(6):611–613; discussion 614.
  467. Chang W.T., Lee K.T., Chuang S.C., Wang S.N., Kuo K.K., Chen J.S., et al. The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy: a prospective randomized study. Am J Surg. 2006;191(6):721–725.
  468. Shea J.A., Berlin J.A., Bachwich D.R., Staroscik R.N., Malet P.F., McGuckin M., et al. Indications for and outcomes of cholecystectomy: a comparison of the pre and postlaparoscopic eras. Ann Surg. 1998;227(3):343–350.
  469. Kallen A.J., Wilson C.T., Larson R.J. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol. 2005;26(12):916–922.
  470. Page C.P., Bohnen J.M., Fletcher J.R., McManus A.T., Solomkin J.S., Wittmann D.H. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg. 1993;128(1):79–88.
  471. Martin C. Antimicrobial prophylaxis in surgery: general concepts and clinical guidelines. French study group on antimicrobial prophylaxis in surgery, French society of anesthesia and intensive care. Infect Control Hosp Epidemiol. 1994;15(7):463–471.
  472. Slim K., Vicaut E., Panis Y., Chipponi J. Meta-analysis of randomized clinical trials of colorectal surgery with or without mechanical bowel preparation. Br J Surg. 2004;91(9):1125–1130.
  473. Güenaga K.F., Matos D., Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev. 2011;(9):CD001544.
  474. Garibaldi R.A. Prevention of intraoperative wound contamination with chlorhexidine shower and scrub. J Hosp Infect. 1988;11 Suppl B:5–9.
  475. Kaiser A.B., Kernodle D.S., Barg N.L., Petracek M.R. Influence of preoperative showers on Staphylococcal skin colonization: a comparative trial of antiseptic skin cleansers. Ann Thorac Surg. 1988;45(1):35–38.
  476. Seropian R., Reynolds B.M. Wound infections after preoperative depilatory versus razor preparation. Am J Surg. 1971;121(3):251–254.
  477. Tanner J., Norrie P., Melen K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev. 2011;(11):CD004122.
  478. Melling A.C., Ali B., Scott E.M., Leaper D.J. Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. Lancet. 2001;358(9285):876–880.
  479. Kurz A., Sessler D.I., Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. study of wound infection and temperature group. N Engl J Med. 1996;334(19):1209–1215.
  480. Moller A.M., Villebro N., Pedersen T., Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet. 2002;359(9301):114–117.
  481. Talbot T.R. Diabetes mellitus and cardiothoracic surgical site infections. Am J Infect Control. 2005;33(6):353–359.
  482. Latham R., Lancaster A.D., Covington J.F., Pirolo J.S., Thomas C.J. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol. 2001;22(10):607–612.
  483. Zerr K.J., Furnary A.P., Grunkemeier G.L., Bookin S., Kanhere V., Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg. 1997;63(2):356–361.
  484. Valentine R.J., Weigelt J.A., Dryer D., Rodgers C. Effect of remote infections on clean wound infection rates. Am J Infect Control. 1986;14(2):64–67.
  485. Edwards L.D. The epidemiology of 2056 remote site infections and 1966 surgical wound infections occurring in 1865 patients: a four year study of 40,923 operations at Rush-Presbyterian-St. Luke’s Hospital, Chicago. Ann Surg. 1976;184(6):758–766.
  486. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):250-78; quiz 279-280.
  487. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K., et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283.
  488. Anderson D.J., Podgorny K., Berrios-Torres S.I., Bratzler D.W., Dellinger E.P., Greene L., et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(6):605–627.
  489. World Health Organization. Global guidelines for the prevention of surgical site infection. [Internet]. 2016 [cited 2017 May 19]. Available from: http://www.who.int/gpsc/ssi-prevention-guidelines/en/
  490. Berríos-Torres S.I., Umscheid C.A., Bratzler D.W., Leas B., Stone E.C., Kelz R.R., et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017.
  491. The National Institute for Health and Care Excellence. Surgical site infections: prevention and treatment [Internet]. 2017 [cited 2017 May 31]. Available from: https://www.nice.org.uk/guidance/cg74
  492. Pan I.W., Kuo G.M., Luerssen T.G., Lam S.K. Impact of antibiotic prophylaxis for intrathecal baclofen pump surgery in pediatric patients. Neurosurg Focus. 2015;39(6):E10.
  493. Hospenthal D.R., Murray C.K., Andersen R.C., Bell R.B., Calhoun J.H., Cancio L.C., et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. J Trauma. 2011;71(2 Suppl 2):S210-234.
  494. Hauser C.J., Adams C.J., Eachempati S.R. Surgical Infection Society guideline: prophylactic antibiotic use in open fractures: an evidence-based guideline. Surg Infect. 2006;7(4):379–405.
  495. Hoff W.S., Bonadies J.A., Cachecho R., Dorlac W.C. East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma. 2011;70(3):751–754.
  496. Lack W.D., Karunakar M.A., Angerame M.R., Seymour R.B., Sims S., Kellam J.F., et al. Type III open tibia fractures: immediate antibiotic prophylaxis minimizes infection. J Orthop Trauma. 2015;29(1):1–6.
  497. Nelson R.L., Gladman E., Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2014;(5):CD001181.
  498. Chen M., Song X., Chen L.Z., Lin Z.D., Zhang X.L. Comparing mechanical bowel preparation with both oral and systemic antibiotics versus mechanical bowel preparation and systemic antibiotics alone for the prevention of surgical site infection after elective colorectal surgery: A meta-analysis of randomized controlled clinical trials. Dis Colon Rectum. 2016;59(1):70–78.
  499. Kiran R.P., Murray A.C., Chiuzan C., Estrada D., Forde K. Combined preoperative mechanical bowel preparation with oral antibiotics significantly reduces surgical site infection, anastomotic leak, and ileus after colorectal surgery. Ann Surg. 2015;262(3):416-25; discussion 423-425.
  500. Morris M.S., Graham L.A., Chu D.I., Cannon J.A., Hawn M.T. Oral antibiotic bowel preparation significantly reduces surgical site infection rates and readmission rates in elective colorectal surgery. Ann Surg. 2015;261(6):1034–1040.
  501. Mackeen A.D., Packard R.E., Ota E., Berghella V., Baxter J.K. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. Cochrane Database Syst Rev. 2014;(12):CD009516.
  502. Tita A.T.N., Rouse D.J., Blackwell S., Saade G.R., Spong C.Y., Andrews W.W. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009;113(3):675–682.
  503. Smaill F.M., Grivell R.M. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014;(10):CD007482.
  504. Amedee Peret F.J. Perioperative antibiotics to prevent infection after first-trimester abortion | RHL [Internet]. The WHO reproductive health library; Geneva: World Health Organization. 2013 [cited 2017 May 19]. Available from: https://extranet.who.int/rhl/topics/fertility-regulation/induced-abortion/perioperative-antibiotics-prevent-infection-after-first-trimester-abortion
  505. Low N., Mueller M., Van Vliet H.A., Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. Cochrane Database Syst Rev. 2012;(3):CD005217.
  506. Jones D.J., Bunn F., Bell-Syer S.V. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev. 2014;(3):CD005360.
  507. Schweizer M., Perencevich E., McDanel J., Carson J., Formanek M., Hafner J., et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. BMJ. 2013;346:f2743.
  508. Bebko S.P., Green D.M., Awad S.S. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. JAMA Surg. 2015;150(5):390–395.
  509. Tsu J.H., Ma W.K., Chan W.K., Lam B.H., To K.C., To W.K., et al. Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy. Urology. 2015;85(1):15–21.
  510. Naber K.G. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis. 1989;11 Suppl 5:S1321-1337.
  511. Piraino B., Bailie G.R., Bernardini J., Boeschoten E., Gupta A., Holmes C., et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005;25(2):107–131.
  512. Blanca M., Romano A., Torres M.J., Fernandez J., Mayorga C., Rodriguez J., et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy. 2009;64(2):183–193.
  513. Stark B.J., Earl H.S., Gross G.N., Lumry W.R., Goodman E.L., Sullivan T.J. Acute and chronic desensitization of penicillin-allergic patients using oral penicillin. J Allergy Clin Immunol. 1987;79(3):523–532.
  514. DePestel D.D., Benninger M.S., Danziger L., LaPlante K.L., May C., Luskin A., et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc. 2008;48(4):530–540.
  515. Romano A., Gaeta F., Valluzzi R.L., Caruso C., Rumi G., Bousquet P.J. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol. 2010;126(5):994–999.
  516. Antunez C., Blanca-Lopez N., Torres M.J., Mayorga C., Perez-Inestrosa E., Montanez M.I., et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol. 2006;117(2):404–410.
  517. Romano A., Gueant-Rodriguez R.M., Viola M., Pettinato R., Gueant J.L. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med. 2004;141(1):16–22.
  518. Atanaskovic-Markovic M., Gaeta F., Medjo B., Viola M., Nestorovic B., Romano A. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy. 2008;63(2):237–240.
  519. Romano A., Viola M., Gueant-Rodriguez R.M., Gaeta F., Pettinato R., Gueant J.L. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med. 2006;354(26):2835–2837.
  520. Romano A., Viola M., Gueant-Rodriguez R.M., Gaeta F., Valluzzi R., Gueant J.L. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med. 2007;146(4):266–269.
  521. Pichichero M.E., Casey J.R. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol--Head Neck Surg. 2007;136(3):340–347.
  522. Audicana M., Bernaola G., Urrutia I., Echechipia S., Gastaminza G., Muñoz D., et al. Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy. 1994;49(2):108–113.
  523. Miranda A., Blanca M., Vega J.M., Moreno F., Carmona M.J., García J.J., et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol. 1996;98(3):671–677.
  524. Edelstein P.H. Legionella. Man Clin Microbiol. 2011;770–785.
  525. HA Central Committee on Infectious Disease and Emergency response. Legionnaires’ Disease (LD) – Clinical management. 2012.
  526. Bernander S., Gastrin B., Lofgren S., Olinder-Nielsen A.M. Legionella urinary antigen in early disease. Scand J Infect Dis. 1994;26(6):777–778.
  527. Kohler R.B., Winn W.J., Wheat L.J. Onset and duration of urinary antigen excretion in Legionnaires disease. J Clin Microbiol. 1984;20(4):605–607.
  528. Helbig J.H., Uldum S.A., Luck P.C., Harrison T.G. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol. 2001;50(6):509–516.
  529. Blázquez R.M., Espinosa F.J., Martínez-Toldos C.M., Alemany L., García-Orenes M.C., Segovia M. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur J Clin Microbiol Infect Dis. 2005;24(7):488–491.
  530. Wilson M.L., Clinical and Laboratory Standards Institute. Principles and procedures for blood cultures: approved guideline. Wayne, Pa.: Clinical and Laboratory Standards Institute; 2007.
  531. Álvarez R., Viñas-Castillo L., Lepe-Jiménez J.A., García-Cabrera E., Cisneros-Herreros J.M. Time to positivity of blood culture association with clinical presentation, prognosis and ESBL-production in Escherichia coli bacteremia. Eur J Clin Microbiol Infect Dis. 2012;31(9):2191–2195.
  532. Blot F., Schmidt E., Nitenberg G., Tancrede C., Leclercq B., Laplanche A., et al. Earlier positivity of central-venous-versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol. 1998;36(1):105–109.
  533. Kassis C., Rangaraj G., Jiang Y., Hachem R.Y., Raad I. Differentiating culture samples representing coagulase-negative Staphylococcal bacteremia from those representing contamination by use of time-to-positivity and quantitative blood culture methods. J Clin Microbiol. 2009;47(10):3255–3260.
  534. Blot F., Nitenberg G., Chachaty E., Raynard B., Germann N., Antoun S., et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet. 1999;354(9184):1071–1077.
  535. Kim J., Gregson D.B., Ross T., Laupland K.B. Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. J Infect. 2010;61(3):197–204.
  536. Lai C.C., Wang C.Y., Liu W.L., Hou C.C., Huang Y.T., Hsueh P.R. Time to blood culture positivity as a predictor of methicillin resistance in Staphylococcus aureus bacteremia. J Infect. 2011;62(2):190–191.
  537. Peralta G., Rodriguez-Lera M.J., Garrido J.C., Ansorena L., Roiz M.P. Time to positivity in blood cultures of adults with Streptococcus pneumoniae bacteremia. BMC Infect Dis. 2006;6:79.
  538. Neuman M.I., Harper M.B. Time to positivity of blood cultures for children with Streptococcus pneumoniae bacteremia. Clin Infect Dis. 2001;33(8):1324–1328.
  539. Peralta G., Roiz M.P., Sanchez M.B., Garrido J.C., Ceballos B., Rodriguez-Lera M.J., et al. Time-to-positivity in patients with Escherichia coli bacteraemia. Clin Microbiol Infect. 2007;13(11):1077–1082.
  540. Liao C.H., Lai C.C., Hsu M.S., Huang Y.T., Chu F.Y., Hsu H.S., et al. Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective cohort study. Clin Microbiol Infect. 2009;15(12):1119–1125.
  541. Lai C.C., Wang C.Y., Liu W.L., Cheng A., Lee Y.C., Huang Y.T., et al. Time to blood culture positivity as a predictor of drug resistance in Acinetobacter baumannii complex bacteremia. J Infect. 2011;63(1):96–98.
  542. Lai C.C., Wang C.Y., Liu W.L., Huang Y.T., Hsueh P.R. Time to positivity of blood cultures of different Candida species causing fungaemia. J Med Microbiol. 2012;61(Pt 5):701–704.
  543. Atkins B.L., Athanasou N., Deeks J.J., Crook D.W., Simpson H., Peto T.E., et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. the OSIRIS collaborative study group. J Clin Microbiol. 1998;36(10):2932–2939.
  544. Schafer P., Fink B., Sandow D., Margull A., Berger I., Frommelt L. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis. 2008;47(11):1403–1409.
  545. Hughes J.G., Vetter E.A., Patel R., Schleck C.D., Harmsen S., Turgeant L.T., et al. Culture with BACTEC Peds Plus/F bottle compared with conventional methods for detection of bacteria in synovial fluid. J Clin Microbiol. 2001;39(12):4468–4471.
  546. Podleska L.E., Lendemans S., Schmid E., Hussmann B., Nast-Kolb D., Taeger G. Sample taking during orthopedic surgery: sensitivity and specificity using the BACTEC blood culture system. Eur J Clin Microbiol Infect Dis. 2012;31(2):201–206.
  547. Hughes H.C., Newnham R., Athanasou N., Atkins B.L., Bejon P., Bowler I.C. Microbiological diagnosis of prosthetic joint infections: a prospective evaluation of four bacterial culture media in the routine laboratory. Clin Microbiol Infect. 2011;17(10):1528–1530.
  548. Fuller D.D., Davis T.E. Comparison of BACTEC plus Aerobic/F, Anaerobic/F, Peds Plus/F, and Lytic/F media with and without fastidious organism supplement to conventional methods for culture of sterile body fluids. Diagn Microbiol Infect Dis. 1997;29(4):219–225.
  549. Cetin E.S., Kaya S., Demirci M., Aridogan B.C. Comparison of the BACTEC blood culture system versus conventional methods for culture of normally sterile body fluids. Adv Ther. 2007;24(6):1271–1277.
  550. Fuller D.D., Davis T.E., Kibsey P.C., Rosmus L., Ayers L.W., Ott M., et al. Comparison of BACTEC plus 26 and 27 media with and without fastidious organism supplement with conventional methods for culture of sterile body fluids. J Clin Microbiol. 1994;32(6):1488–1491.
  551. Akcam F.Z., Yayli G., Uskun E., Kaya O., Demir C. Evaluation of the BACTEC microbial detection system for culturing miscellaneous sterile body fluids. Res Microbiol. 2006;157(5):433–436.
  552. Bourbeau P., Riley J., Heiter B.J., Master R., Young C., Pierson C. Use of the BacT/Alert blood culture system for culture of sterile body fluids other than blood. J Clin Microbiol. 1998;36(11):3273–3277.
  553. Bobadilla M., Sifuentes J., Garcia-Tsao G. Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol. 1989;27(10):2145–2147.
  554. Tuberculosis & Chest Service, Department of Health, The Government of the Hong Kong Special Administrative Region. Tuberculosis and Chest Service Department of Health - List of journal publications related to tuberculosis in Hong Kong [Internet]. 2015 [cited 2017 May19]. Available from: http://www.info.gov.hk/tb_chest/contents/c57.htm
  555. Tuberculosis & Chest Service, Department of Health, the Government of the Hong Kong Special Administrative Region. Guidelines on targeted tuberculin testing and treatment of latent tuberculosis infection – Tuberculosis and Chest Service. (Updated March 2015) [Internet]. 2015. Available from: http://www.info.gov.hk/tb_chest/doc/LTBI_guide_TBCS_2012_update%201%20Nov2013_ADD_31March2015.pdf
  556. Tuberculosis & Chest Service, Department of Health, The Government of the Hong Kong Special Administrative Region. Ambulatory treatment and public health measures for a patient with uncomplicated pulmonary tuberculosis – an information paper (Jan 2013) [Internet]. 2013 [cited 2017 May 18]. Available from: http://www.info.gov.hk/tb_chest/doc/Information_paper_ambulatory_tb_2013.pdf